Inhibition of tissue factor reduces thrombus formation and intimal hyperplasia after porcine coronary angioplasty.

OBJECTIVES We investigated the in vivo effects of tissue factor (TF) inhibition with recombinant tissue factor pathway inhibitor (rTFPI) on acute thrombus formation and intimal hyperplasia and the in vitro effects on smooth muscle cell migration and proliferation. BACKGROUND Inhibition of TF with TFPI has been shown to reduce intimal hyperplasia in experimental models. However, its effects after coronary angioplasty and the cellular mechanisms involved have not been investigated. METHODS Twenty-three swine underwent multivessel coronary angioplasty. Fifteen (n = 25 arteries) were euthanized at 72 h to assess thrombus formation and eight (n = 24 arteries) at 28 days to assess intimal hyperplasia. Animals in the 72-h time point received: 1) human rTFPI (0.5 mg bolus plus 25 microg/kg/min continuous infusion for 3 days) plus heparin (150 IU/kg intravenous bolus) plus acetyl salicylic acid (ASA) (325 mg/day); 2) rTFPI regimen plus ASA and 3) heparin (150 IU/kg intravenous bolus) plus ASA. RESULTS On histology the control group had evidence of mural thrombus (area 0.8+/-0.4 mm2). Treatment with TFPI plus heparin abolished thrombus formation (mean area: 0.0+/-0.0 mm2, p < 0.05) but was associated with prolonged activated partial thromboplastin time and extravascular hemorrhage. Recombinant TFPI alone inhibited thrombosis without bleeding complications (mean area: 0.03+/-0.02 mm2, p < 0.05 vs. control). Animals in the 28-day time point received continuous intravenous infusion of rTFPI or control solution for 14 days. Tissue factor pathway inhibitor reduced neointimal formation with mean intimal area of 1.2+/-0.3 mm2 versus 3.2+/-0.4 mm2 in the control group; p < 0.01. Recombinant TFPI had no effect on human aortic smooth muscle cell growth but inhibited platelet-derived growth factor BB-induced migration. CONCLUSIONS Inhibition of TF with rTFPI can prevent acute thrombosis and intimal hyperplasia after injury. Tissue factor plasma inhibitor may prove useful as an adjunct to intracoronary interventions.

[1]  V. Fuster,et al.  Prolonged Thrombin Inhibition Reduces Restenosis After Balloon Angioplasty in Porcine Coronary Arteries , 1996 .

[2]  Y. Miyagi,et al.  A Role for Tissue Factor in Cell Adhesion and Migration Mediated by Interaction with Actin-binding Protein 280 , 1998, The Journal of cell biology.

[3]  G. Fager.  Thrombin and proliferation of vascular smooth muscle cells. , 1995, Circulation research.

[4]  I. Tsuji,et al.  Comparison of plasma tissue factor levels in unstable and stable angina pectoris. , 1998, The American journal of cardiology.

[5]  A. Gori,et al.  Elevated Tissue Factor and Tissue Factor Pathway Inhibitor Circulating Levels in Ischaemic Heart Disease Patients , 1998, Thrombosis and Haemostasis.

[6]  K. Kugiyama,et al.  Plasma tissue factor pathway inhibitor and tissue factor antigen levels after administration of heparin in patients with angina pectoris. , 1999, Thrombosis research.

[7]  C. Lye.  Balloon angioplasty—Natural history of the pathophysiological response to injury in a pig model: Steele PM, Chesebro JH, Stanson AW, et al. Circulation 1985; 57:105-12 , 1987 .

[8]  V. Fuster,et al.  Hirudin reduces tissue factor expression in neointima after balloon injury in rabbit femoral and porcine coronary arteries. , 1998, Circulation.

[9]  T. Abumiya,et al.  An anti-tissue factor pathway inhibitor (TFPI) monoclonal antibody recognized the third Kunitz domain (K3) of free-form TFPI but not lipoprotein-associated forms in plasma. , 1995, Journal of biochemistry.

[10]  W. Roberts,et al.  Effectiveness of Recombinant Desulphatohirudin in Reducing Restenosis After Balloon Angioplasty of Atherosclerotic Femoral Arteries in Rabbits , 1991, Circulation.

[11]  E. Topol,et al.  Thrombosis of a flexible coil coronary stent: frequency, predictors and clinical outcome. , 1993, Journal of the American College of Cardiology.

[12]  J. Miletich,et al.  Cloning and characterization of a cDNA coding for the lipoprotein-associated coagulation inhibitor shows that it consists of three tandem Kunitz-type inhibitory domains. , 1988, The Journal of biological chemistry.

[13]  Burton E. Sobel,et al.  Prevention of Arterial Reocclusion After Thrombolysis With Recombinant Lipoprotein‐Associated Coagulation Inhibitor , 1991, Circulation.

[14]  S. Moore,et al.  Thrombin generation and fibrin formation following injury to rabbit neointima. Studies of vessel wall reactivity and platelet survival. , 1982, Laboratory investigation; a journal of technical methods and pathology.

[15]  G. Sicard.  Platelet-derived growth factor activity and mRNA expression in healing vascular grafts in baboons , 1992 .

[16]  V. Fuster,et al.  Balloon angioplasty. Natural history of the pathophysiological response to injury in a pig model. , 1985, Circulation research.

[17]  Samin K. Sharma,et al.  Identification of active tissue factor in human coronary atheroma. , 1996, Circulation.

[18]  V. Kakkar,et al.  Cellular effects of heparin on the production and release of tissue factor pathway inhibitor in human endothelial cells in culture. , 1999, Arteriosclerosis, thrombosis, and vascular biology.

[19]  V. Fuster,et al.  Local inhibition of tissue factor reduces the thrombogenicity of disrupted human atherosclerotic plaques: effects of tissue factor pathway inhibitor on plaque thrombogenicity under flow conditions. , 1999, Circulation.

[20]  J. Isner,et al.  How Does Angioplasy Work?: Serial Analysis of Human Iliac Arteries Using Intravascular Ultrasound , 1992, Circulation.

[21]  R. Altman,et al.  Efficacy of Unfractionated Heparin, Low Molecular Weight Heparin and Both Combined for Releasing Total and Free Tissue Factor Pathway Inhibitor , 1998, Pathophysiology of Haemostasis and Thrombosis.

[22]  S. Wickline,et al.  Inhibition of tissue factor-mediated coagulation markedly attenuates stenosis after balloon-induced arterial injury in minipigs. , 1997, Circulation.

[23]  K. Kugiyama,et al.  Heightened tissue factor associated with tissue factor pathway inhibitor and prognosis in patients with unstable angina. , 1999, Circulation.

[24]  B. Lindblad,et al.  Antithrombotic effect of recombinant truncated tissue factor pathway inhibitor (TFPI1-161) in experimental venous thrombosis--a comparison with low molecular weight heparin. , 1994, Thrombosis and haemostasis.

[25]  R. Ross,et al.  Platelet-derived growth factor activity and mRNA expression in healing vascular grafts in baboons. Association in vivo of platelet-derived growth factor mRNA and protein with cellular proliferation. , 1991, The Journal of clinical investigation.

[26]  Division on Earth.  Guide for the Care and Use of Laboratory Animals , 1996 .

[27]  M. Blombäck,et al.  Relationship of Tissue Factor Pathway Inhibitor Activity to Plasma Lipoproteins and Myocardial Infarction at a Young Age , 1994, Thrombosis and Haemostasis.

[28]  Y. Nemerson.  Tissue Factor: Then and Now , 1995, Thrombosis and Haemostasis.

[29]  P. Amouyel,et al.  Predictors of restenosis after coronary stent implantation. , 1998, Journal of the American College of Cardiology.

[30]  B. Giusti,et al.  Tissue Factor Reduction and Tissue Factor Pathway Inhibitor Release after Heparin Administration , 1999, Thrombosis and Haemostasis.

[31]  E. Topol,et al.  Influence of blockade at specific levels of the coagulation cascade on restenosis in a rabbit atherosclerotic femoral artery injury model. , 1995, Circulation.

[32]  V. Fuster,et al.  The Three Processes Leading to Post PTCA Restenosis: Dependence on the Lesion Substrate , 1995, Thrombosis and Haemostasis.

[33]  J. Bittl,et al.  Advances in coronary angioplasty. , 1996, The New England journal of medicine.

[34]  Robert G. Johnson,et al.  Neointimal thickening after severe coronary artery injury is limited by a short-term administration of a factor Xa inhibitor. Results in a porcine model. , 1996, Circulation.

[35]  R E Vlietstra,et al.  Restenosis and the proportional neointimal response to coronary artery injury: results in a porcine model. , 1992, Journal of the American College of Cardiology.

[36]  K. Hatakeyama,et al.  Tissue Factor Induces Migration of Cultured Aortic Smooth Muscle Cells , 1996, Thrombosis and Haemostasis.

[37]  J. Fallon,et al.  Tissue factor expression in human arterial smooth muscle cells. TF is present in three cellular pools after growth factor stimulation. , 1997, The Journal of clinical investigation.

[38]  V. Fuster,et al.  Tissue factor modulates the thrombogenicity of human atherosclerotic plaques. , 1997, Circulation.

[39]  B. Sobel,et al.  Maintenance of coronary patency after fibrinolysis with tissue factor pathway inhibitor. , 1995, Circulation.

[40]  G. Broze,et al.  Tissue factor pathway inhibitor and the revised theory of coagulation. , 1995, Annual review of medicine.

[41]  A. Guha,et al.  Tissue factor is rapidly induced in arterial smooth muscle after balloon injury. , 1993, The Journal of clinical investigation.